{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274596","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.050389+00:00","generated_at":"2026-05-16T22:27:10.445015+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia reports positive lonvo-z HAE data: 97% attack-free; nex-z shows 87% TTR reduction at 36 months","bullets":["Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).","Mean kallikrein reduction 89% at month 24; well-tolerated safety up to 3 years with no long-term risks.","Nex-z Phase 1: 87% mean serum TTR reduction at 36 months (n=9); all-cause mortality rate 3.9 vs 12.7 per 100 patient-years (HR 0.27, p=0.009) vs matched cohort.","Nex-z showed disease stability or improvement on multiple cardiomyopathy markers at 24 months; 81% stable/improved NYHA class.","FDA clinical hold on nex-z Phase 3 MAGNITUDE/MAGNITUDE-2 trials; company working to address."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274596","json":"https://secwatch.observer/filing/0001193125-25-274596.json","markdown":"https://secwatch.observer/filing/0001193125-25-274596.md","text":"https://secwatch.observer/filing/0001193125-25-274596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/0001193125-25-274596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/d12611d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:27:10.445015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}